News February 2024

Smivet BV has recently published a peer-reviewed scientific paper on the development of its single-domain antibody (SDA) platform to extent the serum half life of biologics in multiple animal species. The article in Frontiers in Immunology (Harmsen, Ackerschott and De Smit 2014) describes the various approaches made and the clinical evaluation of several candidates from the available platform that can be used cross-species. The publication is the result of a past and further continuing research effort to enable use of the SDA technology for  treatment of various diseases in Animal Health.